Inside Precision Medicine November 22, 2023
Early cancer detection company Grail announced the start of a study to assess the clinical impact of the company’s Galleri multi-cancer early detection test among Medicare beneficiaries, with a specific focus on racial and ethnic minorities in historically underserved communities.
The Real-world Evidence to Advance Multi-Cancer Early Detection Health Equity (REACH/Galleri-Medicare study) aims to include up to 50,000 Medicare beneficiaries who will receive usual care along with an annual Galleri test, compared to a matched comparator arm receiving only usual care. Medicare will cover the costs of the test and associated routine items and services for participants. Given that age is a significant risk factor for cancer, the study targets Medicare beneficiaries who face a substantial unmet need for early...
Today's Sponsors
Today's Sponsor